Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Executive Summary
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
You may also be interested in...
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
Preparing for COVID 2.0: Understanding Animal ‘Spillover’ And Addressing Excessive Nationalism
Former Merck executive Julie Gerberding, Biocon chief Kiran Mazumdar-Shaw, ModeX Therapeutics’ John Mascola, and NIH’s Larry Tabak discuss what it will take to better handle the next pandemic.